Open AccessTyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience
Author(s) -
Karthik Bommannan,
Shano Naseem,
Jogeshwar Binota,
Neelam Varma,
Pankaj Malhotra,
Subhash Varma
Publication year - 2022
Publication title -
journal of postgraduate medicine/journal of postgraduate medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 52
eISSN - 0972-2823
pISSN - 0022-3859
DOI - 10.4103/jpgm.jpgm_781_20
Subject(s) - medicine , mutation , chronic myelogenous leukemia , tyrosine kinase inhibitor , tyrosine kinase , protein kinase domain , polymerase chain reaction , cd135 , cancer research , leukemia , genetics , gene , cancer , biology , mutant , receptor
Despite the impressive responses achieved with tyrosine kinase inhibitor (TKI) therapy, treatment resistance develops in 16-33% of patients of chronic myelogenous leukemia (CML). Of the BCR-ABL1 dependent mechanisms, mutations in the tyrosine kinase domain (TKD) are the commonest cause of resistance.